These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35512517)

  • 1. Evaluation of
    Bailey TA; Wacker JN; An DD; Carter KP; Davis RC; Mocko V; Larrabee J; Shield KM; Lam MN; Booth CH; Abergel RJ
    Nucl Med Biol; 2022; 110-111():28-36. PubMed ID: 35512517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of
    Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR
    J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of CD46 targeted alpha theranostics in prostate cancer using
    Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
    Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclotron-Produced
    Aluicio-Sarduy E; Barnhart TE; Weichert J; Hernandez R; Engle JW
    J Nucl Med; 2021 Jul; 62(7):1012-1015. PubMed ID: 33127622
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
    Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
    J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of bifunctional chelates for (64)Cu antibody imaging.
    Ferreira CL; Yapp DT; Crisp S; Sutherland BW; Ng SS; Gleave M; Bensimon C; Jurek P; Kiefer GE
    Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2117-26. PubMed ID: 20552190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and preclinical studies of
    Lam K; Chan C; Reilly RM
    MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
    Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Kondo M; Cai Z; Chan C; Forkan N; Reilly RM
    EJNMMI Radiopharm Chem; 2023 Sep; 8(1):24. PubMed ID: 37750937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the PET in vivo generator
    Bauer D; De Gregorio R; Pratt EC; Bell A; Michel A; Lewis JS
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of the PET in vivo generator
    Bauer D; De Gregorio R; Pratt EC; Bell A; Michel A; Lewis JS
    Eur J Nucl Med Mol Imaging; 2024 Nov; 51(13):4015-4025. PubMed ID: 38940841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
    Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
    Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.
    Antczak C; Jaggi JS; LeFave CV; Curcio MJ; McDevitt MR; Scheinberg DA
    Bioconjug Chem; 2006; 17(6):1551-60. PubMed ID: 17105236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.